Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.65 |
| ▸ | LSS | P48449 | 1/20 | 0.62 |
| ▸ | LTA4H | P09960 | 3/20 | 0.58 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.58 |
| ▸ | ESR1 | P03372 | 5/20 | 0.57 |
| ▸ | ESRRG | P62508 | 1/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10806159 | 0.98 | KDM4E (0.67) | KDM4EALDH1A1SMN1; SMN2HRH3LSS | |
| SCHEMBL2477011 | 0.90 | ESR1 (0.65) | KDM4EALDH1A1HRH3LTA4HESR1 | |
| SCHEMBL9671156 | 0.89 | KDM4E (0.83) | KDM4EALDH1A1SMN1; SMN2HRH3LSS | |
| SCHEMBL6057395 | 0.88 | ALDH1A1 (0.57) | KDM4EALDH1A1SMN1; SMN2HRH3LSS | |
| SCHEMBL8226392 | 0.82 | KDM4E (0.71) | KDM4EALDH1A1SMN1; SMN2HRH3LSS | |
| SCHEMBL3220867 | 0.81 | BCHE (0.60) | SMN1; SMN2HRH3 | |
| SCHEMBL3220854 | 0.81 | BCHE (0.60) | SMN1; SMN2HRH3 | |
| SCHEMBL3260775 | 0.81 | HRH3 (0.71) | KDM4EALDH1A1SMN1; SMN2HRH3LSS | |
| SCHEMBL3664138 | 0.81 | ALDH1A1 (0.65) | KDM4EALDH1A1SMN1; SMN2HRH3LSS | |
| SCHEMBL2473527 | 0.80 | LTA4H (0.68) | LTA4HNR5A1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042855-A1 | PERIPHERALLY AND LUMINALLY-RESTRICTED INHIBITORS OF THE SEROTONIN TRANSPORTER AS TREATMENTS FOR DISORDERS OF GASTROINTESTINAL MOTILITY AND GUT-BRAIN AXIS | THE JOHNS HOPKINS UNIVERSITY | 2025-02-06 | — | — | US | disclosed |
| US-7915280-B2 | Compounds and their uses | EISAI INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-RE41150-E1 | Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one | EISAI CORPORATION OF NORTH AMERICA (US) | 2010-02-23 | — | — | US | disclosed |
| US-7235557-B2 | Compounds and their uses | MGI GP, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20060142266-A1 | Compounds and their uses | MGI GP, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| US-20060003987-A1 | Compounds and their uses | GUILFORD PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | US | disclosed |
| US-20050148575-A1 | (Di)Azepino[5,4,3-cd]benzothiophenes; poly(ADP-ribose) polymerase (PARP) and glycohydrolase (PARG) inhibitor; antiinflammatory; protects cells, tissue and organs against the ill-effects of reactive free radicals and nitric oxide, and damage following focal ischemia and reperfusion injury | GUILFORD PHARMACEUTICALS INC. (US) | 2005-07-07 | — | — | US | disclosed |
| US-6887996-B2 | Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one | GUILFORD PHARMACEUTICALS INC. (US) | 2005-05-03 | — | — | US | disclosed |
| EP-1339402-A2 | BENZOAZEPINE AND BENZODIAZEPINE DERIVATIVES AND THEIR USE AS PARP INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030022883-A1 | Compounds and their use | EISAI INC. | 2003-01-30 | — | — | US | disclosed |
| WO-2002044183-A2 | BENZOAZEPINE AND BENZODIAZEPINE DERIVATIVES AND THEIR USE AS PARP INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022883-A1 | Compounds and their use | PARP1, PARP2, PARP3 | KDM4E 1317/4885ALDH1A1 1256/4885SMN1; SMN2 2136/4885 |
| US-20060003987-A1 | Compounds and their uses | PARP1, PARP2, PARP3 | KDM4E 1628/4885ALDH1A1 1283/4885SMN1; SMN2 1993/4885 |
| US-20050148575-A1 | (Di)Azepino[5,4,3-cd]benzothiophenes; poly(ADP-ribose) polymerase (PARP) and glycohydrolase (PARG) inhibitor; antiinflammatory; protects cells, tissue and organs against the ill-effects of reactive free radicals and nitric oxide, and damage following focal ischemia and reperfusion injury | PARP1, PARP11, PARP15 | KDM4E 1317/4885ALDH1A1 360/4885SMN1; SMN2 4045/4885 |
| US-20250042855-A1 | PERIPHERALLY AND LUMINALLY-RESTRICTED INHIBITORS OF THE SEROTONIN TRANSPORTER AS TREATMENTS FOR DISORDERS OF GASTROINTESTINAL MOTILITY AND GUT-BRAIN AXIS | SLC6A4, HTR6, HTR5A | KDM4E 2944/4885ALDH1A1 4569/4885SMN1; SMN2 1920/4885 |
| US-20060142266-A1 | Compounds and their uses | PARP1, PARP2, PARP3 | KDM4E 1628/4885ALDH1A1 1283/4885SMN1; SMN2 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.